APP and Alzheimer disease: This hypothesis is supported by research using different mouse models for AD (APP/PS1, 3xTg and APPsw/Ind), where it was shown that when GLT1 expression is pharmacologically increased, levels of synaptophysin and PSD-95 increase (Zumkehr et al., 2015; Hefendehl et al., 2016), and even cognitive function improves (Takahashi et al., 2015).